Providing expert support in Medicinal Chemistry, Drug Discovery, Pharmaceutical Research, Project Leadership, Relationship Management and Corporate Contracts.

• Led multidisciplinary teams in the progression and execution of business opportunities to deliver on the strategic goals of the Diabetes Care Companies.• Led the negotiation and execution of a new Commercialization Agreement with a key business partner; reduced cost by 20% and increased our access to data.• Enhanced Diabetes Care digital portfolio through the execution of agreements with strategic partner.• Developed landscape assessments of consumer medical technology products for potential acquisition or integration into Diabetes Care Companies’ portfolio.• Supported Diabetes Care in the execution of strategic options leading to the closure of Animas and divestiture of the LifeScan businesses.

• Rebuilt a preclinical portfolio through the repurposing internal assets; built a scientific case, obtained endorsement from the Leadership Team and identified collaborators to run key experiments.• Drove the creation of a target-specific alliance in macular edema with a small biotech.• Led the evaluation of four in-licensing opportunities for the treatment of macular degeneration.• Prioritized potential biotech partners engaged in ophthalmic gene therapy from >40 companies. • Managed relationships with preclinical development scientists to ensure data packages were appropriate for the declaration of ophthalmic clinical candidates and progression into clinical trials.

• Contributed to the creation and evaluation of a global scientific landscape designed to identify new areas of R&D investment for GSK – led to the creation of a group dedicated to shepherding new and novel programs through existing infrastructure.• Facilitated, with a SVP sponsor, a new medicinal chemistry resourcing model designed to enhance Program Teams’ ability to more efficiently deliver quality candidate molecules.

• Built and led scientific diligence teams in the evaluation of biotech assets with the goal of creating multi-program alliances; provided scientific input and criteria for Collaboration Agreements.• Led the review of >10 Development Candidates; reviewed output from >15 screening campaigns and associated Lead milestone packages; drove program prioritization decisions; presided over the review of milestone decisions; represented the CEEDD at R&D governance meetings.• Provided chemistry support in the scientific diligence leading to a company acquisition; transitioned three lead-stage programs into the GSK R&D organization.• Led the review of novel science or disease areas (e.g., fragment-based drug discovery, sleep apnea, hearing loss) resulting in interaction with or diligence on a number of companies.• Led strategic discussions on program planning, clinical trial design and milestone criteria.

• Matrix Team Leader (Program Leader) from 2002 – delivered 2 clinical candidates, 4 leads and evaluated the output of several high-throughput screens.• Chemistry leader with line responsibility for up to nine chemists; managed teams of up to sixteen.• Lead chemist responsible for the design, synthesis and purification of target small molecules; contributed to more than ten lead optimization programs across target classes leading to Clinical Candidates and several pre-candidate molecules.• Managed departmental capital budget to ensure that department-owned equipment was sufficient for up to 70 chemists.